Home » Topics » Infection, BioWorld Science

Infection, BioWorld Science
RSS

BerGenBio updates progress from phase II studies of bemcentinib in COVID-19

April 19, 2021

Discovery of EU-129 for treatment of severe COVID-19 in patients with underlying diseases

April 19, 2021

BOLD-100 shows robust preclinical efficacy against COVID-19 variants

April 19, 2021

Carrimycin studied in phase III to treat severe COVID-19 in hospitalized patients

April 19, 2021

Icatibant portion of I-SPY COVID trial ends after futility criterion met

April 16, 2021

Merck & Co. discontinues development of MK-7110 for COVID-19

April 16, 2021

INO-4800 provides broad cross-reactive immune responses against variant strains of SARS-CoV-2

April 16, 2021

First volunteer dosed in phase I study of COVID-19 candidate HLX-71

April 16, 2021

Phase III study of ciclesonide inhaler in COVID-19 does not meet statistical significance

April 16, 2021

GLS-1027 studied in phase II to prevent severe pneumonitis caused by SARS-CoV-2

April 16, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...